Johnson & Johnson (JNJ) Earnings Call Analysis

NYSE · Healthcare · Drug Manufacturers - General

Earnings Reports

• Johnson & Johnson (JNJ) Q2 2026: Innovative Medicine Drives $400M Guidance Raise, MedTech Faces Cardiovascular Drag
  July 15, 2026
• Johnson & Johnson (JNJ) Q1 2026: Icotide Launch Drives 7.4% Innovative Medicine Growth, Raising Full-Year Outlook
  April 14, 2026
• Johnson & Johnson (JNJ) Q4 2025: Oncology Surges 21% as Portfolio Shift Targets Double-Digit Growth
  January 21, 2026
• Johnson & Johnson (JNJ) Q3 2025: Orthopedics Separation Targets 75bps Margin Lift, Accelerating MedTech Focus
  October 14, 2025
• Johnson & Johnson (JNJ) Q2 2025: Oncology Jumps 22% as Portfolio Depth Offsets Stellara LOE
  July 17, 2025
• Johnson & Johnson (JNJ) Q1 2025: Diversified Model Delivers Growth Despite Stellara Erosion and Margin Headwinds
  June 10, 2025

Browse all companies